Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Colorectal Neoplasms 36Breast Neoplasms 29Pancreatic Neoplasms 20Rectal Neoplasms 17Stomach Neoplasms 16Neoplasm Metastasis 16Neoplasms 12Esophageal Neoplasms 8Triple Negative Breast Neoplasms 7Colonic Neoplasms 7Colorectal Cancer Metastatic 6Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Brain Neoplasms 4Adenocarcinoma 4Head and Neck Neoplasms 3Gastrointestinal Neoplasms 3Biliary Tract Neoplasms 3Bile Duct Neoplasms 3Advanced Solid Tumors 3Sarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Liver Neoplasms 2Diabetes Mellitus, Insulin-Dependent, 12 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2

Interventions

pyrotinib 1Lapatinib 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × HER2 Positive Metastatic Breast Cancer × Capecitabine × Clear all
NCT02422199 2018-07-09

A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Unknown
128 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡